Search
Aptevo Therapeutics Inc
APVOAdd to Watchlist
4.180USD
+0.220+5.56%
Close 08-07 16:00（ET）Quotes delayed by 15 min
6.35MMarket Cap
0.00P/E TTM
Forecast
Currency: USD Updated: 2026-08-07The current earnings forecast score of Aptevo Therapeutics Inc is 8.00, ranking 171 out of 387 in the Biotechnology & Medical Research industry. The average price target is 420.00, with a high of 420.00 and a low of 420.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.500
Target Price
+526.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Aptevo Therapeutics Inc
APVO
1
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Aptevo Therapeutics Inc's price target?
Analysts forecast that Aptevo Therapeutics Inc's price target is USD 420.00, with the highest forecast at USD 420.00 and the lowest forecast at USD 420.00.
How have Aptevo Therapeutics IncAPVO's recent earnings per share performed?
The market expectation was USD -6.41, while Aptevo Therapeutics IncAPVO's earnings per share (EPS) for the previous quarter was USD -6.23. EPS for the next quarter is expected at USD -6.01.
What is the analyst rating for Aptevo Therapeutics Inc?
Based on the ratings of Aptevo Therapeutics Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.